Analyst consensus rating
Allogene Therapeutics Analyst Rating: Strong Buy
ALLO is rated Strong Buy by 9 analysts with a $9.00 target. As of 2026-08-23.
Direct answer
Allogene Therapeutics's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.00.
Forecast evidence checked August 23, 2026.
Get free Allogene Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.09
- Average price target
- $9.00
- High price target
- $14.00
- Low price target
- $4.00
- Low target gap
- +91.4%
- Target upside
- +330.6%
- High target gap
- +569.9%
- Target range width
- 478.5%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Allogene Therapeutics?
Allogene Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $9.00.
How far are Allogene Therapeutics's low and high targets from the recorded price?
The low target implies +91.4%, while the high target implies +569.9%.
How many analysts are included in Allogene Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Allogene Therapeutics's target upside or downside calculated?
The average target of $9.00 is divided by the recorded price of $2.09, then one is subtracted to produce +330.6%. This does not guarantee a future return.
When was Allogene Therapeutics's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.